BioCentury

1:49 AM GMT, May 22, 2010
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Clinical News

Ipilimumab meets NSCLC endpoint

Bristol-Myers Squibb Co. (NYSE:BMY) said both regimens of 10 mg/kg ipilimumab every

Read the full 128 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.